Comparison Overview
Hikma Pharmaceuticals

Hikma Pharmaceuticals
1 New Burlington Place, London, W1S 2HR, GB
Last Update: 03/04/2026
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospita...

Grifols
Parc Empresarial Can Sant Joan, Sant Cugat del Vallès, 08174, ES
Last Update: 04/04/2026
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healt...
Compliance Ranges Comparison

Hikma Pharmaceuticals







Grifols






Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Grifols in 2026.
Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)
Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Grifols (X = Date, Y = Severity)
Grifols cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents

Hikma Pharmaceuticals

Grifols
FAQ
Latest Global CVEs
PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.
PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.
PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.
PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.
PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.